Entering text into the input field will update the search result below

Amgen Lumakras combination data in lung cancer held until August - Reuters

Jul. 12, 2022 7:14 PM ETAmgen Inc. (AMGN) Stock, MRK Stock, RHHBY Stock, MRTX StockSNY, RVMDBy: Jonathan Block, SA News Editor

Lung cancer. lung disease. 3d illustration

Mohammed Haneefa Nizamudeen

  • Data on Amgen's Lumakras (sotorasib) in combination with Merck's (NYSE:MRK) Keytruda (pembrolizumab) and Roche's (OTCQX:RHHBY) Tecentriq (atezoliuzumab) will be released on Aug. 7 instead of this month, Reuters reported.
  • Results will be released at the 2022 World

Recommended For You

More Trending News

Related Stocks

SymbolLast Price% Chg
AMGN--
Amgen Inc.
MRK--
Merck & Co., Inc.
RHHBY--
Roche Holding AG
MRTX--
Mirati Therapeutics, Inc.